EGFR inhibitors prolong survival in non-small-cell lung cancer
A new meta-analysis shows their superiority over chemotherapy
Adjunct targeted molecular therapy may prolong disease-free survival in patients with resected non-small cell lung cancer harbouring epidermal growth factor receptor mutations, a meta-analysis suggests.
Chinese researchers have reviewed the role of epidermal growth factor receptor tyrosine kinase inhibitors (eGFR-TKIs) after surgery for non-small cell lung cancer as the clinical value has been uncertain.
